Achilles Therapeutics plc announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2021. For the quarter, the company reported loss from operations was $16,289,000 against $6,942,000 a year ago. Net loss was $16,156,000 against $6,855,000 a year ago. Basic and diluted loss per share was $0.45 against $7.64 a year ago. For the six months, the company reported loss from operations was $29,997,000 against $12,508,000 a year ago. Net loss was $29,921,000 against $12,069,000 a year ago. Basic and diluted loss per share was $1.6 against $13.57 a year ago.